September 16, 2021 4:54pm

The Biostage (BSTG) Chronicles: Same and usual “tricks” as the customary “pump/promote” continued, on Thursday as BSTG open -$0.04 with 461 shares traded, suddenly 14,641 were traded with the shares down -$0.04. The SEC should question who or which entity is buying these shares – there is a pattern?

Pre-open indications: 5 HITs and 0 MISS

My comments try to distinguish the temporary from real pricing digression or progress with a 360-degree view.

 

The Dow closed DOWN -63.07 points (-0.18%); the S&P closed DOWN -6.95 points (-0.16%) while the Nasdaq closed UP +20.40 points (+0.13%)

 

Henry’omics:

Indexes slipped, yet the Nasdaq eked-out an upside on Thursday despite better-than-expected August retail sales, as the latest weekly jobless claims report pointed to a mixed economic picture.

Friday marks a key date for the market as the final third of September historically sees the worst performance of the month. <CNBC>

 

Data Docket: August retail sales surprised the market and rose 0.7% from the month prior, the Census Bureau reported Thursday. Economists expected a 0.8% month-over-month decline after the initial estimate for July was revised down sharply from a month-over-month gain of 0.5% to a decline of 1.8%.

  • The latest unemployment insurance weekly data showed 332,000 first-time jobless claims last week. Economists expected a total of 320,000 initial claims.

 

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines:

  • Thursday opened negative at 8/25, 1 flat and 1 acquired, stayed negative at the mid-day at 12/21, 1 flat and 1 acquired, closing positive at 16/13, 5 flats and 1 acquired;

 

RegMed Investors’ (RMi) pre-open: “exit early, meaning today. Quadruple witching will occur on Friday as stock and index futures and options are set to expire at the same time” …  https://www.regmedinvestors.com/articles/12097

 

Pre-open results: 5 Hits <BUY: Global Blood Therapeutics (GBT +$0.38), Editas Medicine (EDIT +$ 0.70), Intellia Therapeutics (NTLA +$3.41), Sage Therapeutics (SAGE +$0.32), Biostage (BSTG -$0.04 – “pumped”)> 0 Miss

 

The Biostage (BSTG) Chronicles: “The Biostage (BSTG) Chronicles - Maintaining Sell - Is this another Theranos – faking it to not make it?” … https://www.regmedinvestors.com/articles/12087

 

Q2/21 Earnings releases … https://www.regmedinvestors.com/articles/11542  … to date:

  • Net Income: 3 and Net losses: 23
  • Applied Genetic Technologies (AGTC) reports 9/23

 

Key Metric - volume:

  • Sector volume was LOW with 2 of the 16-upside having higher than the 3-month average volume with very LOW volume of 3 of 13-downside having higher than the 3-month average volume;

 

The Biostage (BSTG) Chronicles: The usual “pump/promote”, on Thursday closing -$0.04 with 14,641 shares traded after Wednesday opened down -$0.04 (404 shares traded) and then promptly jumped +$0.52 with 17,107 shares traded after Tuesday closed down -$0.27 to $3.56 with 6,551 shares traded following Monday’s +$0.04 to $3.83 with 26,150 shares traded, Fridays closed down -$0.19 to $3.79 with 22,124 shares traded after Thursday traded up +$0.66 to $3.98 with 6,0622 shares traded, Wednesday traded +$0.57 with 7,833 shares traded after last Tuesday closing down -$0.75 to $2.75 with 6,705 shares traded.

  • Today is just another fact, how the share trades with the “push/promote” - another typical example,
  • WHAT is BSTG’s value proposition, after all the share price “pumping”?
  • Is management responding to U.S./non-U.S./ Chinese investors complaints after the last (listed pricing) private placement of $4.71?
  • Where are these buying monies coming from?

 

There are clear winners and losers

Jumping with share pricing momentum:

  • Intellia therapeutics (NTLA), Alnylam Pharmaceuticals (ALNY), Editas Medicine (EDIT), uniQure NV (QURE), Global Blood Therapeutics (GBT) to name 5 of the 16 inclining of the 35 covered

Hammered in today’s market:

  • BioLife Solutions (BLFS) - again, Vericel (VCEL), Ultragenyx (RARE), Regenxbio (RGNX) - again, Ionis Pharmaceuticals (IONS) to name 5 of the 13 declining of the 35 covered

Closing flat:

  • 5 – ReNeuron (RENE.L), Pluristem (PSTI), mesoblast (MESO), Homology Medicine (FIXX), Chinook Therapeutics (FIXX) and 1- Stemline Therapeutics (STML) – acquired

 

Stats:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Thursday, the IBB closed up +0.41% and XBI closed up +0.44%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Thursday was up +0.51 points or +2.81% at 18.69

 

September, the third month of Q3/21:

Thursday closed positive with 16 advancers, 13 decliners, 5 flat and 1 acquired

Wednesday closed positive with 18 advancers, 14 decliners, 2 flat and 1 acquired

Tuesday closed negative with 5 advancers, 29 decliners and 1 acquired

Monday (9/13) closed negative with 15 advancers, 19 decliners and 1 acquired

 

The BOTTOM LINE: The stem, cell and gene therapy sector barely managed to buck the downward pressure.

Friday has been a historically weak session for stocks as those September losses typically come in the back half of the month.

When you’re on a roller coaster, the only thing you can be sure of is you’ll end up back where you started.

I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”

WHY do I keep analyzing Biostage (BSTG): When one sees an inextricable wrong and morally repulsive scenario; it takes courage, resolve and patience to stay the course of asking the questions without response!

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence – it’s more than opinion, the facts and truth need to be recognized!

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.